Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2016-05-20 | Dimitrios J. Angelis is a Director since May 2015. He serves as Chairman of the Audit Committee and is a member of the Compensation and Nominations and Corporate Governance Committees. His total compensation was $71,073. |
| 2018-07-16 | Our Board of Directors currently has three standing committees. The current members of our committees are identified below: Committees Director Audit Compensation Nominations and Corporate Governance Dimitrios J. Angelis X X (Chair) Jeffrey E. Eberwein X X Robert Pearse X X (Chair) Venkatraman Balakrishnan X (Chair) X Srinidhi Devanur, our Executive Vice Chairman, does not serve on any of our standing committees. The Audit Committee currently consists of Messrs. Angelis, Pearse and Balakrishnan, with Mr. Balakrishnan serving as chairman. The Audit Committee held five meetings during the year ended December 31, 2017. All members of the Audit Committee (i) are independent directors (as currently defined in Rule 5605(a)(2) of the NASDAQ listing rules); (ii) meet the criteria for independence set forth in Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”); (iii) have not participated in the preparation of the financial statements of the Company or any current subsidiary of the Company at any time during the past three years; and (iv) are able to read and understand fundamental financial statements. Mr. Angelis qualifies as an “Audit Committee financial expert” as defined in the rules and regulations established by the SEC. The Audit Committee is governed by a written charter approved by our Board of Directors. The functions of the Audit Committee include, among other things: • Meeting with our management periodically to consider the adequacy of our internal controls and the objectivity of our financial reporting; • Meeting with our independent registered public accounting firm and with internal financial personnel regarding the adequacy of our internal controls and the objectivity of our financial reporting; • Recommending to our Board of Directors the engagement of our independent registered public accounting firm; • Reviewing our quarterly and audited consolidated financial statements and reports and discussing the statements and reports with our management, including any significant adjustments, management judgments and estimates, new accounting policies and disagreements with management; and • Reviewing our financial plans and reporting recommendations to our full Board of Directors for approval and to authorize action. Both our independent registered public accounting firm and internal financial personnel regularly meet privately with our Audit Committee and have unrestricted access to the Audit Committee. The Compensation Committee currently consists of Messrs. Eberwein and Pearse, with Mr. Pearse serving as chairman. The Compensation Committee held two meetings during the year ended December 31, 2017. Messrs. Eberwein and Pearse are independent, as determined under the various NASDAQ Stock Market, SEC and Internal Revenue Service qualification requirements. The Compensation Committee is governed by a written charter approved by our Board of Directors. The charter of the Compensation Committee permits the Compensation Committee to engage outside consultants and to consult with our human resources department when appropriate to assist in carrying out its responsibilities. Compensation consultants have not been engaged by the Company to recommend or assist in determining the amount or form of compensation for any current executive officers or directors of the Company. The Committee may also obtain advice and assistance from internal or external legal, accounting, or other advisers selected by the Committee. The functions of the Compensation Committee include, among other things: • Reviewing and, as it deems appropriate, recommending to our Board of Directors, policies, practices, and procedures relating to the compensation of our directors, officers and other managerial employees and the establishment and administration of our employee benefit plans; • Establishing appropriate incentives for officers, including the Chief Executive Officer, to encourage high performance, promote accountability and adherence to company values and further our long-term strategic plan and long-term value; and • Exercising authority under our employee benefit plans. The Nominations and Corporate Governance Committee currently consists of Messrs. Angelis, Eberwein and Balakrishnan, with Mr. Angelis serving as chairman. The Nominations and Corporate Governance Committee held two meetings during the year ended December 31, 2017. Messrs. Angelis, Eberwein and Balakrishnan are independent directors (as currently defined in Rule 5605(a)(2) of the NASDAQ listing rules). The Nominations and Corporate Governance Committee is governed by a written charter approved by our Board of Directors. The functions of the Nominations and Corporate Governance Committee include, among other things: • Reviewing and recommending nominees for election as directors; • Assessing the performance of our board of directors; • Developing guidelines for the composition of our board of directors; • Reviewing and administering our corporate governance guidelines and considering other issues relating to corporate governance; and • Oversight of the Company compliance officer and compliance with the Company’s Code of Ethics and Business Conduct and Code of Ethics for our Chief Executive Officer and Senior Financial Officers. |
| 2018-08-22 | Dimitrios J. Angelis Consists of 40,990 shares of common stock and 25,000 shares of common stock issuable upon exercise of options exercisable within 60 days. |
| 2019-09-27 | The Audit Committee consists of Messrs. Angelis, Sukumaran and Martella. The Compensation Committee consists of Messrs. Angelis and Sukumaran. The Nominations and Corporate Governance Committee consists of Mr. Angelis. The following table sets forth the cash compensation, as well as certain other compensation earned by each person who served as a director of our company, during the year ended December 31, 2018: Dimitrios J. Angelis Includes 27,386 RSUs granted on multiple dates during 2018 Valued at an average $2.57 per share for a total of $70,408. |
| 2020-11-04 | The Audit Committee consists of Messrs. Angelis, Sukumaran and Martella. ... Mr. Angelis qualifies as an “Audit Committee financial expert” ... The Compensation Committee consists of Messrs. Angelis and Sukumaran. ... The Nominations and Corporate Governance Committee consists of Mr. Angelis. ... The following table sets forth the cash compensation, as well as certain other compensation earned by each person who served as a director of our company, during the year ended December 31, 2019: ... Dimitrios J. Angelis 72,000 |
| Filing Date | Source Excerpt |
|---|---|
| 2017-03-22 | Dimitrios J. Angelis Age 47 Director since 2015 Executive Counsel, Life Sciences Law Group Committees: Audit, Compensation, Corporate Governance (Chairman) Mr. Angelis was appointed as a director of the Company on July 30, 2015. In addition to Digirad, Mr. Angelis currently serves as a director of Ameri100, a position he has held since May 2015; and as director of On Track Innovations Ltd (“OTI”) since December 30, 2012. From April 26, 2013 until February 9, 2015, Mr. Angelis served as the OTI’s Chairman of the Board of Directors. Mr. Angelis currently serves as Principal of Life Sciences Law Group, a post he has held since October 2015. From January 2014 to August 2015 he served as Chief Executive Officer of OTI America (a subsidiary of OTI). Since 2012 until immediately prior to his appointment as Chief Executive Officer of OTI America, Mr. Angelis was the General Counsel of Wockhardt Inc., a biologics and pharmaceutical company. From 2008 to 2012, Mr. Angelis was a senior counsel in Dr. Reddy’s Laboratories, Ltd., a publicly traded pharmaceutical company, and during 2008 he was the Chief Legal Officer and Corporate Secretary of Osteotech, Inc., a publicly traded medical device company. Prior to that, Mr. Angelis worked in the pharmaceutical and legal industries in various corporate, strategic and legal roles, including the Corporate department of the New York office of Mayer Brown LLP. Mr. Angelis holds a B.A. in Philosophy and English from Boston College, an M.A. in Behavioral Science from California State University, and Juris Doctor from New York University School of Law and is admitted to practice law in the state of New York and New Jersey. We believe Mr. Angelis' past positions in the health care industry and his legal experience make him well qualified to serve on our Board of Directors. These experiences allow him to offer unique insight into our operations for the purpose of guiding the Company Board of Directors to the right legal and strategic decisions. Non-Employee Director Compensation Table Name Fees Paid in Cash ($) Stock Awards ($) (4) Option Awards ($) Non-Equity Incentive Plan Compensation ($) Change in Pension Value and Nonqualified Deferred Compensation Earnings ($) All Other Compensation ($) Total ($) Dimitrios J. Angelis 49,000 68,125 — — — — 117,125 |
| 2018-03-22 | Dimitrios J. Angelis Age 48 Director since 2015 Executive Counsel, Life Sciences Law Group Committees: Audit, Compensation, Corporate Governance (Chairman) ...Non-Employee Director Compensation Table...Dimitrios J. Angelis...Fees Paid in Cash ($) 49,000...Stock Awards ($) 46,875...Total ($) 95,875 |
| 2019-03-26 | Dimitrios J. Angelis Age 49 Director since 2015 Executive Counsel, Life Sciences Law Group Committees: Audit, Compensation, Corporate Governance (Chairman) ... Dimitrios J. Angelis 49,000 Fees Paid in Cash ($), 23,125 Stock Awards ($), Total 72,125 |
Data sourced from SEC filings. Last updated: 2026-02-03